A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers

Ulrik N Lassen, Didier Meulendijks, Lilian L Siu, Vaios Karanikas, Morten Mau-Sorensen, Jan H M Schellens, Derek J Jonker, Aaron R Hansen, Mary E Simcox, Kathleen J Schostack, Dean Bottino, Hua Zhong, Markus Roessler, Suzana M Vega-Harring, Tiantom Jarutat, David Geho, Ka Wang, Mark DeMario, Glenwood D Goss